New First-line Option for Advanced Colorectal CancerNew First-line Option for Advanced Colorectal Cancer

In patients with advanced colorectal cancer, the rate of 5-year overall survival was twice as high with FOLFOXIRI plus bevacizumab as with FOLFIRI plus bevacizumab. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news